Clinical Trials on Infiltrating Bladder Urothelial Carcinoma

Total 1092 results

National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Triple-Negative Breast Carcinoma and other conditions

United States, Canada
Celldex Therapeutics

Completed

Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer (CDX1307-02)

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Bladder Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Bladder Small Cell Neuroendocrine Carcinoma | Extrapulmonary Small Cell Neuroendocrine Carcinoma | Recurrent Lung... and other conditions

United States
BioAtla, Inc.

Recruiting

A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

Melanoma | Carcinoma | Renal Cell Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | NSCLC | Cervical Carcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Australia
LG Chem

Not yet recruiting

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors (LB-LR1109)

Urothelial Carcinoma | Malignant Melanoma | Non-small Cell Lung Cancer(NSCLC) | Head and Neck Squamous Cell Carcinoma(HNSCC) | Renal Cell Carcinoma(RCC)
Genocea Biosciences, Inc.

Terminated

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Melanoma | Renal Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Urothelial Carcinoma | Anal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Celgene

Completed

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Tumor Virus Infections | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Carcinoma, Transitional Cell | Carcinoma, Pancreatic Ductal

Spain, United States, France, Netherlands
Massachusetts General Hospital
Conquer Cancer Foundation

Active, not recruiting

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (UPLIFT)

Stage IV Non-Small Cell Lung Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Immunotherapy | Immune Checkpoint Inhibitors | Stage IV Gastric Cancer | Stage IV Merkel Cell Carcinoma | Stage IV Colorectal Cancer | Stage IV Esophageal Cancer | Advanced Lung Cancer | Stage IV Renal... and other conditions

United States
pharmaand GmbH
Gilead Sciences

Terminated

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Ovarian Cancer | Solid Tumor | Urothelial Carcinoma | Triple-negative Breast Cancer

United States
Amgen

Terminated

Safety Study of AMG 228 to Treat Solid Tumors

Melanoma | Cancer | Colorectal Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Oncology | Tumors | Advanced Malignancy | Oncology Patients | Transitional Cell Carinoma of Bladder

Belgium, France, United States, Germany, Australia
Yonsei University

Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

Prostate Cancer | Bladder Cancer | Renal Cell Cancer | Ureter Cancer

Korea, Republic of
NextCure, Inc.

Completed

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Melanoma | Breast Cancer | Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Advanced or Metastatic Solid Tumors | CRC

United States
Herlev Hospital

Completed

Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Malignant Melanoma

Denmark
Pfizer

Terminated

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

United States
Taiho Oncology, Inc.

Completed

A Study of TAS-120 in Patients With Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors

France, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
Tempest Therapeutics

Active, not recruiting

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Colorectal Cancer | Solid Tumor | Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Solid Tumors With PIK3Ca Mutation

United States
Kantonsspital Winterthur KSW

Completed

Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program

Renal Cell Carcinoma | Breast Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Pleural Mesothelioma | Gastro-Intestinal Cancer

Switzerland
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Celon Pharma SA
National Center for Research and Development, Poland

Recruiting

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Sarcoma | Gastric Cancer | Cholangiocarcinoma | Bladder Cancer | Endometrial Cancer | Squamous Non-small Cell Lung Cancer | Other Solid Tumours

Poland
Ludwig-Maximilians - University of Munich

Completed

Fear of Cancer Recurrence in Genitourinary Cancer

Prostate Cancer | Urothelial Carcinoma | Renal Cell Cancer | Fear of Cancer Recurrence | Testicle Cancer

Germany
Sarcoma Oncology Research Center, LLC
Aadi Bioscience, Inc.

Completed

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Ewing Sarcoma | Non Small Cell Lung Cancer | Chordoma | Urothelial Carcinoma | Classical Hodgkin Lymphoma | PEComa | Desmoid Tumor | Epithelioid Sarcoma | Squamous Cell Carcinoma | MTOR Activating Mutation

United States
BicycleTx Limited

Recruiting

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Carcinoma, Non-Small-Cell Lung | Triple Negative Breast Neoplasms | Advanced Solid Tumor | Ovarian Neoplasm | Urinary Bladder Neoplasm

United States, United Kingdom, France, Spain, Italy, Canada
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
Yonsei University

Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Prostate Cancer | Bladder Cancer | Renal Cell Cancer | Ureter Cancer | Urological Malignancies

Korea, Republic of
Pfizer

Recruiting

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Melanoma | Neoplasms | Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

Puerto Rico, Japan, United States
Hoffmann-La Roche

Completed

A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors (KAMELEON)

Bladder Cancer | Pancreas Cancer | Cholangiocellular Carcinoma

Spain, Italy, Netherlands, Slovakia
Famewave Ltd.

Terminated

Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Melanoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Bladder Cancer | Non-small Cell Lung Carcinoma (NSCLC)

United States, Israel
Sun Yat-sen University

Unknown

A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors

Renal Cell Carcinoma | Breast Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Non-small-cell Lung Cancer | Bladder Cancer

China
University of Maryland, Baltimore
National Cancer Institute (NCI)

Completed

LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer

United States
PureTech

Recruiting

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Metastatic Cancer | Urothelial Carcinoma

United States
Cofactor Genomics, Inc.
Curebase Inc.

Recruiting

A Multicenter Cancer Biospecimen Collection Study

Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Cancer of Head and Neck | Lung Cancer, Nonsmall Cell | Gastroesophageal Junction Adenocarcinoma

United States
Travera Inc
John B. Amos Cancer Center

Not yet recruiting

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Carcinoma, Renal Cell | Carcinoma | Carcinoma, Non-Small-Cell Lung | Carcinoma, Hepatocellular | Carcinoma, Pancreatic | Mesothelioma | AML | Cholangiocarcinoma | Stage IV Lung Cancer | Carcinoma, Neuroendocrine | Stage IV Breast Cancer | Carcinoma, Ductal | Malignant Ascites | Carcinoma Prostate | Stage III Breast Cancer and other conditions

United States
Shanghai Fengxian District Central Hospital
Shanghai Yuansong Biotechnology Co., LTD

Recruiting

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study (YSCH-01)

Melanoma | Breast Cancer | Head and Neck Cancer | Lung Cancer | Bladder Cancer | Cervical Carcinoma | Ovarian Carcinoma

China
Institut Mutualiste Montsouris
Institut National de la Santé Et de la Recherche Médicale, France

Recruiting

Vascular Toxicities of Immune ChecKpoint Inhibitors : From Bed to Benchside (VICKI)

Renal Cell Carcinoma | Cancer | Bladder Cancer | MSI-H Cancer

France
The Affiliated Hospital of Qingdao University

Completed

Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System

Renal Cell Carcinoma | Bladder Cancer | Adrenal Tumor

China
MacroGenics

Completed

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Melanoma | Head and Neck Cancer | Non Small Cell Lung Cancer | Urethelial Carcinoma

United States
Shenzhen Second People's Hospital
Shenzhen Institute for Innovation and Translational Medicine

Unknown

T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies

Melanoma | Breast Cancer | Multiple Myeloma | Ovarian Cancer | Lung Cancer | Neuroblastoma | Bladder Carcinoma | Synovial Sarcoma | Esophagus Carcinoma | Other Metastatic Solid Cancers

China
AstraZeneca
ImaginAb, Inc.

Terminated

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

Carcinoma, Non-Small-Cell Lung | Urinary Bladder Neoplasms | Colorectal Cancer

United States, Canada
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
Centre Georges Francois Leclerc

Recruiting

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)

Metastatic Renal Cell Carcinoma | Metastatic Non Small Cell Lung Cancer | Metastatic Head and Neck Cancer | Metastatic Bladder Cancer

France
Xennials Therapeutics Australia Pty Ltd
Pinotbio, Inc.

Terminated

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Advanced Solid Tumor | High-grade Glioma | Platinum-Resistant Ovarian Cancer | Platinum-Resistant Urothelial Carcinoma

Australia
Incyte Corporation

Completed

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Melanoma | Breast Cancer | Head and Neck Cancer | Pancreatic Cancer | Lung Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer) | MMR-deficient Tumors

United States
Molecular Templates, Inc.

Recruiting

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Microsatellite Instability High | Mismatch Repair Deficiency

United States
Klus Pharma Inc.

Recruiting

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264)

Breast Cancer | Non-Small Cell Lung Cancer | Gastric Adenocarcinoma | Epithelial Ovarian Cancer | Head and Neck Squamous Cell Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Gastroesophageal Junction Adenocarcinoma | Small-Cell Lung Cancer

United States, China
VA Office of Research and Development
Baylor College of Medicine; Michael E. DeBakey VA Medical Center; Birmingham...

Active, not recruiting

Measuring and Improving the Safety of Test Result Follow-Up

Breast Cancer | Lung Cancer | Bladder Cancer | Colon Cancer | Hepatocellular Cancer

United States
National Cancer Institute (NCI)

Completed

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

Kidney Cancer | Prostate Cancer | Bladder Cancer

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Recurrent Prostate Cancer | Fallopian Tube Cancer | Bone Metastases | Lung Metastases | Stage III Renal Cell Cancer | Liver Metastases | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Inflammatory Breast Cancer | Metastatic Transitional Cell Cancer of the... and other conditions

United States
GB006, Inc., a wholly owned subsidiary of Gossamer...
Merck Sharp & Dohme LLC

Terminated

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Esophageal... and other conditions

United States, United Kingdom
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States

Clinical Trials on Infiltrating Bladder Urothelial Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations